Loading...
•
Jun 30, 2024
Vir Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024 and announced strategic restructuring to prioritize clinical-stage pipeline opportunities.
Key Takeaways
Vir Biotechnology reported a net loss of $138.4 million for the second quarter of 2024. The company is strategically restructuring to focus on hepatitis programs and has signed an exclusive license agreement with Sanofi. As of June 30, 2024, the company had $1.43 billion in cash, cash equivalents and investments.
Presented positive preliminary Phase 2 chronic hepatitis delta study data at EASL™ Congress 2024.
FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy.
Signed exclusive license agreement with Sanofi to bolster clinical pipeline.
Initiated strategic workforce restructuring and phasing out of influenza, COVID-19, and the Company’s T cell-based viral vector platform programs.
Forward Guidance
The Company is lowering its operating expense guidance for the full-year 2024, inclusive of its recently announced transaction with Sanofi and strategic restructuring.
Positive Outlook
- Savings from workforce restructuring
- Phasing out of influenza programs
- Phasing out of COVID-19 programs
- Phasing out of the Company’s T cell-based viral vector platform programs
- Ongoing cost saving efforts
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...